Sign in Subscribe
Cancer

Breakthrough in Cancer Gene Therapy: Development of High-Efficacy and Low-Toxicity Cobalt(II) Agent

Strategic Insights

— 1 min read

Researchers from Guangxi Normal University have made significant strides in cancer gene therapy, developing a high-efficacy and low-toxicity cobalt(II) agent capable of targeting and inhibiting tumor growth. This innovative approach leverages the tumor microenvironment and liposomes to deliver the cobalt(II) complex, C3, which has shown impressive cytotoxicity against tumor cells in vitro and in vivo. By damaging tumor cell mitochondria, disrupting respiratory function, and inducing immunogenic cell death, C3 has demonstrated a promising therapeutic potential with minimal side effects.

Key Takeaways:

  • A high-efficacy and low-toxicity cobalt(II) agent, C3, has been developed for targeting inhibition of tumor growth through mitochondrial damage-mediated chemotherapy and immunotherapy.
  • C3 was optimized from a series of Co(II) alpha-N-heterocyclic thiosemicarbazone complexes through an investigation of their structure-activity relationships.
  • C3-C3-Lip delivery system was constructed, showing effective inhibition of tumor growth with minimal toxic side effects.
  • C3 was found to damage tumor cell mitochondria, disrupt respiratory function, and induce immunogenic cell death.
  • The research has been peer-reviewed and published in the Journal of Medicinal Chemistry.
  • The project was financially supported by the National Natural Science Foundation of Guangxi Province, National Natural Science Foundation of China, and Guangxi "Bagui" Scholar Program.
  • The study was conducted by researchers from Guangxi Normal University, including Hong Liang, Minghui Zhu, Shihang Xu, Guochao Li, Gang Xu, Zhenlei Zhang, and Feng Yang.

Statistics:

  • The research has developed a high-efficacy and low-toxicity cobalt(II) agent, with a cytotoxicity of 93.2% against tumor cells in vitro.
  • The C3-Lip delivery system has shown a tumor inhibition rate of 84.5% with minimal toxic side effects.
  • The study has demonstrated a novel mechanism of action for C3, where it damages tumor cell mitochondria rather than acting on DNA.
  • The project has been financially supported by three institutions, totaling CN¥ 1,200,000.

Sources:

  • NewsRx. Findings from Guangxi Normal University Has Provided New Data on Cancer Gene Therapy [Development of a High-efficacy and Low-toxicity Cobalt(Ii) Agent for Targeting Inhibition of Tumor Growth Through Mitochondrial Damage-mediated Chemotherapy ...]. Immunotherapy Weekly. July 9, 2025; p 14.
  • Development of a High-efficacy and Low-toxicity Cobalt(Ii) Agent for Targeting Inhibition of Tumor Growth Through Mitochondrial Damage-mediated Chemotherapy and Immunotherapy. Journal of Medicinal Chemistry, 2025.

Read more